Prednisolone or pentoxifylline for alcoholic hepatitis.

  title={Prednisolone or pentoxifylline for alcoholic hepatitis.},
  author={Mark R. Thursz and Paul G. Richardson and Michael Allison and Andrew S. Austin and Megan Bowers and Christopher Paul Day and Nichola Downs and Dermot Gleeson and Alastair J. Macgilchrist and Allister J. Grant and Steven Hood and Steven Masson and Anne Mccune and Jane Mellor and John G O'grady and David Patch and Ian C. Ratcliffe and P. R. Roderick and Louise Stanton and Nikhil Vergis and Mark Wright and Stephen D. Ryder and Ewan H Forrest},
  journal={The New England journal of medicine},
  volume={372 17},
BACKGROUND Alcoholic hepatitis is a clinical syndrome characterized by jaundice and liver impairment that occurs in patients with a history of heavy and prolonged alcohol use. The short-term mortality among patients with severe disease exceeds 30%. Prednisolone and pentoxifylline are both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit persists. METHODS We conducted a multicenter, double-blind, randomized trial with a 2-by-2 factorial design to… 

Figures and Tables from this paper

Pentoxifylline is ineffective in treating severe alcoholic hepatitis

  • P. Hendy
  • Medicine
    Frontline Gastroenterology
  • 2015
The randomized double blind placebo controlled Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial demonstrates that pentoxifyinglline does not improve mortality in severe alcoholic hepatitis at 28 days or beyond, and prednisolone provides a non-significant mortality benefit at28  days which does not persist to 90  Days or beyond.

Therapeutic Strategies for the Treatment of Alcoholic Hepatitis.

More data are needed on the use of liver transplantation in AH as the basis for deriving protocols for selecting cases and for posttransplant management, and the future seems promising for the development of effective and safe pharmacological interventions for severe AH.

Infections in severe alcoholic hepatitis

A high level of suspicion with systematic screening and prompt, adequate treatment are warranted to improve outcomes in patients with severe alcoholic hepatitis, especially in patients who benefit from corticosteroid treatment.

Recent advances in alcoholic hepatitis

More efficacious therapeutic options for AH patients are required with N-acetylcysteine, granulocyte colony stimulating factor, faecal microbiota transplantation and routine antibiotics showing promise, but adequate controlled trials are needed to confirm efficacy.

A Combination of N-Acetylcysteine and Prednisone Has No Benefit Over Prednisone Alone in Severe Alcoholic Hepatitis: A Retrospective Analysis

The combination treatment of NAC + prednisone is not better than prednisone alone in patients with severe alcoholic hepatitis, and DF’+’renal insufficiency had the highest AUROC (0.86) to predict mortality.

Pneumocystis pneumonia after use of corticosteroids in a man with severe alcoholic hepatitis

The case of a 43-year-old male with fatal PCP that occurred after the use of corticosteroids for severe AH illustrates the need for prophylaxis of PCP in individuals with severe AH who are on high-dose cortiosteroids.

Controversies in early liver transplantation for severe alcoholic hepatitis.

Recent literature on this controversy over early liver transplantation in severe AH remains controversial with concerns over the 6-month rule of sobriety and risk of alcohol relapse post-transplant.

Acute Alcoholic Hepatitis

  • J. Rice
  • Medicine
    The Critically Ill Cirrhotic Patient
  • 2019
An understanding of the diagnosis and management of alcoholic hepatitis is essential for those practicing in a critical care setting.

Case of severe alcoholic hepatitis treated with granulocytapheresis

A patient with severe AH complicated by a severe infection caused by the multidrug resistance bacteria (Pseudomonas aeruginosa) was successfully treated with granulocytapheresis monotherapy without using corticosteroids.



Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial.

In patients with alcoholic hepatitis, 4-week treatment with pentoxifylline and prednisolone, compared with prednisolia alone, did not result in improved 6-month survival, and the study may have been underpowered to detect a significant difference in incidence of hepatorenal syndrome, which was less frequent in the group receiving pentoxifyinglline.

Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial

STOPAH aims to be a definitive study to resolve controversy around the existing treatments for alcoholic hepatitis, and will allow two treatments to be evaluated in parallel, with efficient use of patient numbers to achieve high statistical power.

Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial.

Reduced mortality, improved risk-benefit profile and renoprotective effects of pentoxifylline compared with prednisolone suggest that pentoxifyinglline is superior to predisonsolone for treatment of severe alcoholic hepatitis.

Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.

Treatment with PTX improves short-term survival in patients with severe alcoholic hepatitis and appears to be related to a significant decrease in the risk of developing hepatorenal syndrome.

Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis.

Combination therapy with prednisolone plus N-acetylcysteine increased 1-month survival among patients with severe acute alcoholic hepatitis, but 6- month survival, the primary outcome, was not improved and other side effects were similar in the two groups.

Corticosteroid Plus Pentoxifylline Is Not Better than Corticosteroid Alone for Improving Survival in Severe Alcoholic Hepatitis (COPE Trial)

For patients with severe alcoholic hepatitis, a combination of corticosteroids and pentoxifylline has no additional survival advantage compared with cortic Fosteroids alone.

Pentoxifylline for alcoholic hepatitis.

The current available data may indicate a possible positive intervention effect of pentoxifylline on all-cause mortality and mortality due to hepatorenal syndrome, and conversely, an increase in serious and non-serious adverse events.

Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor.

Evaluating the incidence of infection in patients with severe AH before and after corticosteroid treatment found nonresponse to steroids is the key factor in development of infection and prediction of survival and infection screening is warranted but should not contraindicate steroids.